Jardiance (Empagliflozin) Monitoring in Adults 65 and Older

Why Geriatric-Specific Monitoring Matters for Empagliflozin

Adults 65 and older metabolize drugs differently, carry more comorbidities, and take more concurrent medications than younger patients. A monitoring protocol designed for a 50-year-old on empagliflozin alone will miss risks that surface only in the context of polypharmacy, sarcopenia, and age-related renal decline.

In the EMPA-REG OUTCOME trial (N=7,020), 48.2% of participants were aged 65 or older, and empagliflozin reduced cardiovascular death by 38% (HR 0.62, 95% CI 0.49 to 0.77) across the full cohort [1]. A prespecified subgroup analysis published in Circulation confirmed that the cardiovascular benefit persisted in patients over 65, with no significant interaction by age [2]. These results mean that older adults clearly benefit from the drug. The clinical challenge is not whether to prescribe it but how to monitor it safely once it is prescribed.

The American Diabetes Association (ADA) 2024 Standards of Care specifically recommend individualized glycemic targets and medication review for older adults with diabetes, noting that "overtreatment of diabetes is common in older adults and should be avoided" [3]. Empagliflozin sits at the intersection of benefit and risk in this population. It protects the heart and kidneys, but its diuretic-like mechanism, ketogenesis potential, and genital infection profile require structured follow-up.

Renal Function: The Cornerstone of Geriatric SGLT2 Monitoring

Check eGFR and serum creatinine at baseline, at 3 months after initiation, and every 3 to 6 months thereafter. An initial dip in eGFR of up to 5 mL/min/1.73 m² is expected and typically reversible within the first 4 to 12 weeks.

The EMPA-KIDNEY trial (N=6,609) demonstrated that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82) [4]. Age-stratified data from that trial showed consistent benefit in participants over 65. The initial eGFR decline reflects hemodynamic changes at the glomerulus, not structural damage. Clinicians should not discontinue the drug solely because of this early dip.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines state that "SGLT2 inhibitors should be continued unless there is a specific reason to stop, even when eGFR falls below the initiation threshold" [5]. For geriatric patients, a practical threshold is eGFR <20 mL/min/1.73 m², at which point the glucose-lowering effect is minimal and the risk-benefit ratio shifts. Monitoring frequency should increase to every 6 to 8 weeks if eGFR falls below 30 mL/min/1.73 m².

Serum potassium deserves attention in this population. Empagliflozin has a mild natriuretic effect, but older adults on ACE inhibitors, ARBs, or potassium-sparing diuretics may experience unpredictable swings. Check potassium alongside creatinine at each monitoring interval.

Volume Depletion and Orthostatic Hypotension Assessment

Measure sitting and standing blood pressure at every visit. Ask specifically about dizziness on standing, falls, and reduced fluid intake. Volume depletion is the most common adverse event leading to empagliflozin discontinuation in adults over 75.

Empagliflozin produces an osmotic diuresis by blocking glucose reabsorption in the proximal tubule. In younger patients with intact thirst mechanisms and normal renal concentrating ability, this effect is usually mild. Older adults lose both of these compensatory systems. A pooled analysis of empagliflozin phase III data found that volume depletion events occurred in 5.1% of patients aged 75 and older receiving empagliflozin 25 mg, compared to 2.3% receiving placebo [6].

Practical steps for monitoring volume status include the following. First, check orthostatic vitals (blood pressure and heart rate sitting, then after 1 minute standing) at every in-person visit. A systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, should trigger a medication review. Second, weigh the patient at each visit. A drop of 2 kg or more over 2 weeks without intentional dietary change suggests excessive fluid loss. Third, review the diuretic list. Patients already taking furosemide, hydrochlorothiazide, or chlorthalidone face compounded depletion risk. The Endocrine Society recommends halving the loop diuretic dose when adding an SGLT2 inhibitor to a regimen in older adults with heart failure [7].

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine, has noted: "In the elderly, the diuretic effect of SGLT2 inhibitors is both a benefit and a liability. The same volume reduction that protects against heart failure hospitalization can cause falls if we are not watching closely" [8].

Diabetic Ketoacidosis Screening in Older Adults

Educate every geriatric patient (and their caregivers) about euglycemic DKA symptoms. Check point-of-care ketones during any acute illness, perioperative period, or unexplained nausea.

Euglycemic diabetic ketoacidosis (euDKA) is rare, occurring in roughly 0.1% to 0.3% of SGLT2 inhibitor users per year [9]. The danger in older adults is that classic DKA symptoms (nausea, vomiting, abdominal pain, Kussmaul breathing) overlap with more common geriatric presentations like gastroenteritis, dehydration, and pneumonia. Blood glucose may remain below 250 mg/dL, which falsely reassures clinicians who equate DKA with hyperglycemia.

The FDA's 2015 drug safety communication identified specific precipitants: acute illness, surgery, prolonged fasting, reduced carbohydrate intake, and excessive alcohol [10]. Older adults are disproportionately exposed to several of these triggers. A hip fracture requiring urgent surgery, a bout of influenza that suppresses appetite for days, or a new low-carbohydrate diet recommended by a well-meaning family member can each shift metabolism toward ketogenesis while glucose remains deceptively normal.

Monitoring protocol for DKA risk in geriatric patients requires three elements. First, hold empagliflozin 3 days before any planned surgery or procedure requiring general anesthesia. Second, instruct patients and caregivers to check urine or blood ketones if nausea, vomiting, or unusual fatigue develops, especially if oral intake has dropped. Third, during any hospitalization, document SGLT2 inhibitor use prominently and check a beta-hydroxybutyrate level on admission if the patient presents with metabolic acidosis, even if glucose is normal.

Medication Reconciliation and Drug Interaction Monitoring

Review the complete medication list at every monitoring visit, with particular attention to diuretics, insulin, sulfonylureas, and antihypertensives. Polypharmacy is the norm in patients over 65, and empagliflozin's pharmacodynamic interactions multiply with each added drug.

The median number of chronic medications in U.S. adults aged 65 to 79 is 7, and in those 80 and older it rises to 9 [11]. Empagliflozin does not have major cytochrome P450 interactions, making its pharmacokinetic profile relatively clean. The real concern is pharmacodynamic stacking. A patient taking empagliflozin 25 mg, furosemide 40 mg, lisinopril 20 mg, and amlodipine 5 mg faces compounding volume and blood pressure effects that no single-drug trial fully captured.

The ADA and the American Geriatrics Society (AGS) both recommend structured deprescribing assessments for older adults with diabetes [3]. Specific checks to perform at each visit include the following. For insulin: reduce the dose by 10% to 20% when initiating empagliflozin in patients with an A1C below 7.5%, as the combined effect can cause hypoglycemia. For sulfonylureas: consider discontinuation entirely, since the AGS Beers Criteria list long-acting sulfonylureas (glyburide, chlorpropamide) as potentially inappropriate in older adults [12]. For loop diuretics: halve the dose if blood pressure runs below 120/70 or if orthostatic symptoms emerge. For antihypertensives: reassess the target. AGS guidelines suggest a systolic target of <150 mmHg for most adults over 75, which may allow reduction of background antihypertensive therapy once empagliflozin's BP-lowering effect (typically 3 to 5 mmHg systolic) takes hold [13].

Genital Mycotic Infections and Urinary Tract Symptoms

Screen for genital infections at routine visits. Ask directly, as many older patients do not volunteer these symptoms. Genital mycotic infections occur in 5% to 10% of female empagliflozin users and 1% to 3% of males.

SGLT2 inhibitors increase urinary glucose excretion by 60 to 80 grams per day, creating a favorable environment for Candida species in the perineum and genital tract. In a meta-analysis of 86 randomized trials covering 50,880 participants, SGLT2 inhibitors increased genital infection risk with a relative risk of 3.37 (95% CI 2.89 to 3.93) compared to placebo or active comparator [14]. Older women with vaginal atrophy, reduced mobility for hygiene, or immunocompromised states face the highest incidence.

Monitoring should include a brief symptom inquiry at every visit: itching, discharge, dysuria. For patients with recurrent infections (two or more in 6 months), a shared-decision conversation about continuing the drug versus switching to an alternative is appropriate. Topical antifungals (miconazole or clotrimazole) resolve most episodes, and recurrence alone does not mandate discontinuation if cardiovascular or renal benefits outweigh the burden.

Bone Health and Falls: A Geriatric-Specific Concern

Assess fall risk at baseline and annually using a validated tool like the Timed Up and Go (TUG) test. While empagliflozin has not shown the fracture signal seen with canagliflozin, volume-mediated falls remain a concern.

The CANVAS trial raised alarms about fracture risk with canagliflozin, but subsequent analyses of empagliflozin data have not replicated this signal [15]. A pooled analysis of over 15,000 empagliflozin-treated patients found no increased fracture incidence compared to placebo (HR 0.93, 95% CI 0.74 to 1.18) [6]. The bone safety profile appears neutral for empagliflozin specifically.

The indirect fracture risk, through falls precipitated by orthostatic hypotension or dehydration, is the more relevant concern in geriatric prescribing. The CDC reports that one in four adults aged 65 and older falls each year, and falls are the leading cause of injury-related death in this age group [16]. A structured fall-risk assessment at empagliflozin initiation, repeated annually and after any fall event, connects the drug-monitoring protocol to broader geriatric care. If a patient scores above the TUG threshold (greater than 12 seconds), intensified volume-status monitoring and diuretic reduction should follow.

Monitoring Schedule: A Practical Timeline

The following schedule synthesizes guideline recommendations into a single protocol for geriatric empagliflozin monitoring.

Baseline (before or at initiation): eGFR, serum creatinine, potassium, A1C, orthostatic vitals, weight, fall-risk assessment (TUG), full medication reconciliation, DKA education for patient and caregiver.

Week 2 to 4 (phone or telehealth check-in): Ask about polyuria, dizziness on standing, genital symptoms, and oral intake. Confirm the patient is drinking adequate fluids. No labs required unless symptoms suggest volume depletion.

Month 3: eGFR, creatinine, potassium, orthostatic vitals, weight. Reassess diuretic and antihypertensive doses. Address any genital infections. This visit catches the expected initial eGFR dip and confirms it is stabilizing.

Every 3 to 6 months thereafter: Repeat eGFR, creatinine, potassium. Check A1C every 6 months (or every 3 months if adjusting other glucose-lowering agents). Orthostatic vitals, weight, and infection screening at each visit. Full medication reconciliation at least twice per year.

At any acute illness or hospitalization: Hold empagliflozin. Check beta-hydroxybutyrate if metabolic acidosis is present. Resume only after oral intake is reliably restored for 24 to 48 hours.

The 2024 KDIGO guidelines underscore the importance of continuity: "SGLT2 inhibitors should not be stopped during acute illness solely to avoid a theoretical risk; the decision should weigh the patient's overall clinical trajectory" [5]. For most geriatric patients, temporary discontinuation during acute illness followed by prompt reinitiation is the safest approach.

When to Consider Stopping Empagliflozin

Discontinuation should be a deliberate clinical decision, not a reflexive response to age alone. Specific triggers include persistent eGFR below 20 mL/min/1.73 m², recurrent symptomatic hypotension despite diuretic dose reduction, recurrent euglycemic DKA episodes, or repeated falls temporally linked to volume depletion.

The AGS emphasizes that deprescribing conversations should balance life expectancy, functional status, and patient goals of care [12]. A patient aged 85 with advanced dementia and limited life expectancy may no longer benefit from the cardiovascular risk reduction that takes months to years to manifest. A patient aged 72 with preserved cognition and established heart failure may benefit from continuation even if monitoring requires more frequent visits.

Dr. Mikhail Kosiborod, cardiologist at Saint Luke's Mid America Heart Institute, summarized the balance: "The cardiovascular and renal benefits of SGLT2 inhibitors are among the most consistent we have seen in modern cardiology trials. The task is not to withhold these drugs from older patients but to monitor them with the same rigor we apply to anticoagulants" [17].

Geriatric empagliflozin monitoring succeeds when it follows a structured timeline, prioritizes volume status, and treats medication reconciliation as a recurring clinical intervention rather than a one-time administrative task. Adults aged 65 and older with type 2 diabetes, heart failure, or CKD who continue empagliflozin under this protocol can expect the same cardiovascular mortality benefit demonstrated in EMPA-REG OUTCOME: a 38% relative reduction in cardiovascular death, applicable across the age spectrum [1].